Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis

BACKGROUND: Riociguat is a novel soluble guanylate cyclase stimulator, and has been widely used for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH). Some studies found that riociguat had better effects on CTEPH and proved to be safe, but the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Miaofa, Song, Jin, Gu, Shenglong, Zhao, Rui, Li, Mingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183702/
https://www.ncbi.nlm.nih.gov/pubmed/34087896
http://dx.doi.org/10.1097/MD.0000000000026211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183702/
https://www.ncbi.nlm.nih.gov/pubmed/34087896
http://dx.doi.org/10.1097/MD.0000000000026211

Ejemplares similares